Veracyte | VCYT - Operating Expenses

Stock Price
35.72
Daily Change
0.03 0.08%
Monthly
-11.95%
Yearly
0.53%
Q1 Forecast
34.53

Veracyte reported $108.76M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Agenus USD -274.14M 80.46M Sep/2025
Agilent USD 1.42B 57M Sep/2025
Anika Therapeutics USD 146.8M 867K Sep/2025
Arrowhead Research USD 223.22M 10.86M Dec/2025
Bruker USD 900.9M 124.3M Dec/2025
Exact Sciences USD 875.74M 62.51M Sep/2025
Heron Therapeutics USD 38.47M 4M Sep/2024
Illumina USD 903M 69M Dec/2025
Intrexon USD 61.56M 26.1M Jun/2024
Karyopharm Therapeutics USD 61.82M 3.24M Dec/2024
Laboratory Of America USD 3.13B 32.4M Dec/2025
Ligand Pharmaceuticals USD 8.29M 32.17M Sep/2025
Myriad Genetics USD 229M 3.4M Sep/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Siemens EUR 16.57B 2.29B Dec/2025
Sonic Healthcare AUD 4.23B 2.14B Dec/2024
Thermo Fisher Scientific USD 9.91B 867M Dec/2025
Veracyte USD 108.76M 7.09M Sep/2025
Waters USD 661.85M 1.67B Dec/2025